Skip to main content
Skip table of contents

Agora Resources

About Agora

Agora is a web application that hosts high-dimensional human transcriptomic, proteomic, and metabolomic evidence for whether or not genes are associated with Alzheimer’s disease (AD). Agora also contains a list of over 900 nascent drug targets for AD that were nominated by AD researchers. The list of nominated targets was contributed by researchers from the National Institute on Aging's Accelerating Medicines Partnership in Alzheimer's Disease (AMP-AD) consortium and Target Enablement to Accelerate Therapy Development for Alzheimer's Disease (TREAT-AD) centers, as well as other research teams. Other evidence presented in Agora was either generated by AMP-AD and TREAT-AD research teams, or is aggregated from publicly available data sources.

Agora is funded by the National Institute on Aging. It is developed and maintained by Sage Bionetworks. If you have questions, suggestions, or feedback about Agora, please let us know here.

Acknowledging Agora

We encourage you to use the data and insights presented in Agora, and request that you include the following acknowledgement statement when publicly presenting work that benefited from their use:

The results published here are in whole or in part based on data obtained from Agora, a platform initially developed by the NIA-funded AMP-AD consortium that shares evidence in support of AD target discovery. Agora is available at: doi:10.57718/agora-adknowledgeportal

Agora Data and Methods

The following pages contain additional information about the evidence presented Agora:

Visit Agora

Agora is publicly available at:

JavaScript errors detected

Please note, these errors can depend on your browser setup.

If this problem persists, please contact our support.